Xilio's Revenue Surges, But Warrant Liabilities Deepen Net Loss

Ticker: XLO · Form: 10-Q · Filed: Nov 13, 2025 · CIK: 1840233

Sentiment: bearish

Topics: Biotechnology, Oncology, Early-Stage Pharma, Going Concern, Warrant Liabilities, Clinical Trials, Cash Burn

Related Tickers: XLO, ABBV, GILD, RHHBY

TL;DR

**Xilio's revenue jump is a mirage; the 'going concern' warning and warrant liabilities make this a high-risk bet on unproven therapies.**

AI Summary

Xilio Therapeutics, Inc. reported a significant increase in collaboration and license revenue to $19.066 million for the three months ended September 30, 2025, up from $2.263 million in the same period of 2024, and to $30.080 million for the nine months ended September 30, 2025, compared to $4.620 million in 2024. Despite this revenue growth, the company's net loss widened to $16.287 million for the three months ended September 30, 2025, from $14.020 million in 2024, primarily due to a $15.380 million change in the fair value of common stock warrant liabilities. Research and development expenses increased to $14.321 million for the quarter, up from $10.759 million year-over-year, reflecting ongoing preclinical and clinical development. The company's cash and cash equivalents significantly increased to $103.764 million as of September 30, 2025, from $55.291 million at December 31, 2024, bolstered by a follow-on public offering and an AbbVie stock purchase agreement. However, Xilio's recurring losses from operations raise substantial doubt about its ability to continue as a going concern, and its total stockholders' deficit reached $(8.095) million by September 30, 2025, down from $17.598 million at December 31, 2024.

Why It Matters

Xilio's substantial increase in collaboration revenue, particularly from agreements with AbbVie and Gilead, signals potential validation of its early-stage therapeutic pipeline, which could attract further partnerships and investment in the competitive biotech landscape. However, the widening net loss driven by warrant liabilities and persistent operating losses raises critical questions about long-term financial stability and the path to profitability. Investors need to weigh the promise of pipeline development against the significant 'going concern' risk and the potential for further dilution, impacting employee morale and customer confidence in future product availability if funding challenges persist. The company's ability to secure additional capital or achieve clinical milestones will be crucial for its survival and competitive positioning.

Risk Assessment

Risk Level: high — Xilio Therapeutics explicitly states, 'Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern.' This is further evidenced by a total stockholders' deficit of $(8.095) million as of September 30, 2025, a significant decline from $17.598 million at December 31, 2024. The company's net loss for the nine months ended September 30, 2025, was $45.396 million, indicating continued cash burn.

Analyst Insight

Investors should exercise extreme caution and consider Xilio Therapeutics (XLO) a highly speculative investment due to the explicit 'going concern' warning and substantial accumulated deficit. Monitor closely for updates on additional capital raises or significant clinical trial advancements, as these are critical for mitigating the severe financial risks outlined in the 10-Q.

Financial Highlights

debt To Equity
N/A
revenue
$19.066M
operating Margin
-9.67%
total Assets
$133.694M
total Debt
$141.789M
net Income
$(16.287)M
eps
N/A
gross Margin
N/A
cash Position
$103.764M
revenue Growth
+743.5%

Revenue Breakdown

SegmentRevenueGrowth
Collaboration and license revenue$19.066M+743.5%
Collaboration and license revenue (YTD)$30.080M+551.5%

Key Numbers

Key Players & Entities

FAQ

What were Xilio Therapeutics' key financial results for the quarter ended September 30, 2025?

Xilio Therapeutics reported collaboration and license revenue of $19.066 million for the three months ended September 30, 2025, a significant increase from $2.263 million in the prior year. However, the company's net loss widened to $16.287 million, compared to a net loss of $14.020 million in the same period of 2024, largely due to a $15.380 million change in the fair value of common stock warrant liabilities.

Why does Xilio Therapeutics have a 'going concern' warning in its 10-Q filing?

Xilio Therapeutics explicitly states that its 'recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern.' This is supported by an accumulated deficit of $429.149 million as of September 30, 2025, and a total stockholders' deficit of $(8.095) million, indicating that current financial resources may be insufficient to meet future obligations without additional capital.

How much cash and cash equivalents did Xilio Therapeutics have as of September 30, 2025?

As of September 30, 2025, Xilio Therapeutics had $103.764 million in cash and cash equivalents. This represents an increase from $55.291 million at December 31, 2024, primarily due to proceeds from a follow-on public offering and an AbbVie stock purchase agreement.

What is the impact of common stock warrant liabilities on Xilio Therapeutics' financial performance?

The change in fair value of common stock warrant liabilities resulted in a $15.380 million expense for the three months ended September 30, 2025, and a $15.430 million expense for the nine months ended September 30, 2025. This non-cash expense significantly contributed to the company's net loss during these periods.

What are Xilio Therapeutics' primary risks related to its product candidates?

Xilio Therapeutics' business is highly dependent on the success of its early-stage product candidates, which require significant additional preclinical and clinical development. The company's technological approach is unproven, and there is a risk of substantial delays or termination of clinical trials, undesirable side effects, and reliance on third parties for manufacturing and clinical studies, all of which could prevent regulatory approval and commercialization.

Who are Xilio Therapeutics' key collaboration partners mentioned in the 10-Q?

Xilio Therapeutics has established collaborations and strategic partnerships with AbbVie Group Holdings Limited (AbbVie) for a collaboration agreement, Gilead Sciences, Inc. (Gilead) for a license agreement, and F. Hoffmann-La Roche Ltd for a clinical collaboration. These partnerships are crucial for the development and potential commercialization of its product candidates.

What is Xilio Therapeutics' strategy to address its 'going concern' risk?

To alleviate the substantial doubt about its ability to continue as a going concern, Xilio Therapeutics aims to secure sufficient additional capital. If unable to do so, the company will need to implement additional cost reduction strategies, which could involve delaying, limiting, reducing, or eliminating both internal and external costs related to its operations and research and development programs.

How has Xilio Therapeutics' stock ownership changed during the nine months ended September 30, 2025?

During the nine months ended September 30, 2025, Xilio Therapeutics issued 4,347,826 shares of common stock in connection with the AbbVie stock purchase agreement and 1,550,000 shares through at-the-market offerings. The total common shares outstanding increased to 51,829,013 at September 30, 2025, from 45,756,773 at December 31, 2024, indicating dilution.

What are the manufacturing risks for Xilio Therapeutics?

Xilio Therapeutics faces manufacturing risks due to the complexity of producing biologics and its reliance on third-party contract development and manufacturing organizations (CDMOs), including WuXi Biologics (Hong Kong) Limited. These risks include potential manufacturing problems, failure of CDMOs to meet regulatory requirements, limited capacity, and supply interruptions, which could delay development or commercialization.

What is the significance of Xilio Therapeutics being an 'emerging growth company'?

As an emerging growth company under the JOBS Act, Xilio Therapeutics may elect not to use the extended transition period for complying with new or revised financial accounting standards. This designation provides certain regulatory relief, potentially reducing compliance costs, but the company's status as an emerging growth company is temporary.

Risk Factors

Industry Context

The biotechnology industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on strategic partnerships and collaborations to fund development and access expertise. Success is driven by innovation, clinical trial outcomes, and the ability to secure financing.

Regulatory Implications

As a biotechnology company, Xilio is subject to stringent regulations from bodies like the FDA. Clinical trial failures, delays in regulatory approvals, or changes in regulatory requirements can have severe financial and operational consequences. Compliance with evolving healthcare and financial reporting standards is also critical.

What Investors Should Do

  1. Monitor R&D spend and clinical trial progress.
  2. Analyze the sustainability of collaboration revenue.
  3. Evaluate the impact of warrant liability fluctuations.
  4. Assess cash burn rate and future financing needs.

Key Dates

Glossary

Common stock warrant liabilities
Financial instruments that give the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. Changes in their fair value can significantly impact net income. (A substantial $(15.380) million change in fair value negatively impacted Xilio's net loss for Q3 2025.)
Stockholders' (Deficit) Equity
The residual interest in the assets of an entity after deducting all its liabilities. A deficit means liabilities exceed assets. (Xilio reported a stockholders' deficit of $(8.095) million as of September 30, 2025, indicating financial distress.)
Going Concern
An accounting assumption that a business will continue to operate for the foreseeable future. If there is substantial doubt, it must be disclosed. (Xilio's recurring losses raise substantial doubt about its ability to continue as a going concern.)
Collaboration and license revenue
Revenue generated from agreements with other companies for the development, licensing, or commercialization of intellectual property or products. (This is Xilio's primary revenue source, showing dramatic growth in the reported periods.)

Year-Over-Year Comparison

Compared to the prior year, Xilio Therapeutics has experienced a dramatic increase in collaboration and license revenue, growing from $2.263 million to $19.066 million in the third quarter and from $4.620 million to $30.080 million year-to-date. However, this revenue growth has not translated into profitability, as the net loss has widened due to a significant increase in operating expenses, particularly R&D, and a substantial negative adjustment for warrant liabilities. While cash reserves have nearly doubled to $103.764 million, the company's financial position remains precarious, evidenced by a growing stockholders' deficit and concerns about its ability to continue as a going concern.

Filing Stats: 4,371 words · 17 min read · ~15 pages · Grade level 19.4 · Accepted 2025-11-13 07:40:44

Key Financial Figures

Filing Documents

Financial Statements (unaudited)

Financial Statements (unaudited) 7 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 7 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 8 Condensed Consolidated Statements of Stockholders' (Deficit) Equity for the three and nine months ended September 30, 2025 and 2024 9 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 11 Notes to Condensed Consolidated Financial Statements 12 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 41 Item 4.

Controls and Procedures

Controls and Procedures 41 Part II Other Information 42 Item 1A.

Risk Factors

Risk Factors 42 Item 5. Other Information 106 Item 6. Exhibits 107

Signatures

Signatures 108 6 Table of Contents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements XILIO THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share data) (Unaudited) September 30, December 31, 2025 2024 ASSETS Current assets Cash and cash equivalents $ 103,764 $ 55,291 License agreement receivable 17,500 — Prepaid expenses and other current assets 2,825 4,943 Total current assets 124,089 60,234 Restricted cash 1,801 1,782 Property and equipment, net 3,679 4,472 Operating lease right-of-use asset 4,125 4,587 Total assets $ 133,694 $ 71,075 LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY Current liabilities Accounts payable $ 2,300 $ 2,574 Accrued expenses 8,952 9,981 Deferred revenue, current portion 43,846 13,518 Operating lease liability, current portion 1,303 1,188 Total current liabilities 56,401 27,261 Deferred revenue, net of current portion 25,498 19,262 Operating lease liability, net of current portion 5,960 6,954 Common stock warrant liabilities 53,930 — Total liabilities 141,789 53,477 Commitments and contingencies (Note 7) Stockholders' (deficit) equity Preferred stock, $ 0.0001 par value; 5,000,000 shares authorized, no shares issued or outstanding — — Common stock, $ 0.0001 par value; 600,000,000 shares authorized at September 30, 2025 and 200,000,000 shares authorized at December 31, 2024; 51,829,013 shares issued and outstanding at September 30, 2025; 45,756,773 shares issued and outstanding at December 31, 2024 5 5 Additional paid-in capital 421,049 401,346 Accumulated deficit ( 429,149 ) ( 383,753 ) Total stockholders' (deficit) equity ( 8,095 ) 17,598 Total liabilities and stockholders' (deficit) equity $ 133,694 $ 71,075 The accompanying notes are an integral part of these condensed consolidated financial statements. 7 Table of Contents XILIO THERAPEUTICS, INC. Condens

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing